DS Healthcare Group, Inc announced it has appointed Aptiv Solutions as CRO for its proprietary topical prescription treatment.
Aptiv Solutions, as DS Healthcare's CRO, will prepare the company's Investigational New Drug Application (IND) for its proprietary topical hair loss treatment, for submission to the FDA. To date, only one other topical treatment for hair loss has been approved by the FDA. Aptiv Solutions will also conduct a Gap analysis to ensure that DS Healthcare's operations are in line with regulatory requirements for drug approval.
You can read the full release here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.